Ignite Creation Date:
2024-05-06 @ 1:16 AM
Last Modification Date:
2024-10-26 @ 11:02 AM
Study NCT ID:
NCT01777503
Status:
UNKNOWN
Last Update Posted:
2016-10-21
First Post:
2013-01-21
Brief Title:
The Elderly ACS II Trial
Sponsor:
Arcispedale Santa Maria Nuova-IRCCS
Organization:
Arcispedale Santa Maria Nuova-IRCCS
Study Overview
Official Title:
Phase IV A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention PCI
Status:
UNKNOWN
Status Verified Date:
2016-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to compare reduced-dose prasugrel and standard dose clopidogrel in patients older than 74 years with ACS including non-ST-elevation NSTEACS and ST-elevation STEMI patients undergoing early PCI The primary endpoint of the trial will be the one-year composite of all-causedeath myocardial infarction stroke and re-hospitalization due to cardiovascular reasons or bleeding
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None